Additionally, they also included other first-line therapies for HNSCC in their treatment regimen, thereby limiting their capacity to draw conclusions about the efficacy of the TGF-β-inhibiting component of therapy. Here, TGFB1 is linked to head and neck squamous cell carcinoma.